Anti-Obesity Drugs : Market Research Report

Anti-Obesity Drugs

Published by: Global Industry Analysts

Published: Feb. 1, 2009 - 442 Pages

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS: Study Reliability and Reporting Limitations; Disclaimers; Data Interpretation & Reporting Level; Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY: 1.Industry Overview; Current & Future Analysis; Factors Influencing the Market; Obesity - A Global Epidemic; Trends and Issues; Particularly China; 2.Competition; Roche Leads the Race; Competition Grows with Pipeline Drugs; 3.Obesity - An Introduction; Diagnosis of Obesity; Causes of Obesity; Risks Associated with Obesity; 4.Obesity Treatment; Dietary Therapy; Exercise Therapy; Behavior Therapy; Pharmacotherapy; Weight Loss Surgery; Invasive Vis-à-vis Non-invasive Procedures; Bariatric Surgery; Laparoscopic Adjustable Gastric Banding; Vertical Banded Gastroplasty (VBG); Roux-en-Y Gastric Bypass Procedure (RYGB); Lap-Band Procedure; Gastric Band Procedure; Gastric Bypass Procedure; Doudenal Switch; Prescription Drugs Vis-à-vis Non-Prescription Drugs; 5.Anti-Obesity Drugs- An Insight; Introduction; Mechanism of Action; Review of Available Drugs; Anti-obesity Drugs, Brands and Mechanism of Action; Table 5: Global Anti-obesity Prescription Drugs Market (2006): Percentage Share Breakdown of Prescriptions by Physician Practices - Primary Care Physicians (PCP), Internal Medicine, Obsterics/Gynecology, Endocrinology/Diabetes, Psychiatry/Neurology,; Review of Select Drugs Awaiting approval / Under Trials; 6.Recent Clinical Trials; Genaera Initiates First Human Trial of Trodusquemine; Neurogen Completes First Trial of NGD-4715; Alizyme Secures USFDA Approval for Cetilistat Trials; GW Pharma to Start Human Trials of; Epix Completes Phase Ib Trial of PRX - 07034; 7TM Pharma Starts Phase I/II Trial of TM30339; Arena Starts Phase III Clinical Trials of Lorcaserin; Drug Induced Serotonin Could Promote Weight Loss; Takeda Initiates Phase II Clinical Trials of ALT-962; Glenmark to Commence Phase I Trial of; Amylin-Leptin Integrated Therapy to Treat Obesity; Vivus Completes Phase II Trial of Qnexa; VERNALIS Starts Phase I trial for Obesity; 7TM Pharma Completes Phase I/ II Clinical Trials of; Manhattan Pharmaceuticals Starts Phase I trial of; Arena Completes Phase2b Trials of APD356; Metabolic Accomplishes Phase 2b Trials of AOD9604; 7.Product Approvals/Launches; Sanofi-Aventis Receives Swiss Approval for Acomplia; Zydus Cadila Introduces Slimona; Torrent Introduces Rimoslim; Gencor Introduces Slimaluma; Orexigen Develops Excalia; Scripps Research Institute Develops Vaccine for Obesity; Sanofi-Aventis Receives Approval to Market; Sanofi-Aventis Rolls Out Acomplia; Sanofi Secures Approval for Acomplia in the UK; Novo Nordisk to Develop Anti-obesity Drug; Sanofi-Aventis Receives Approval to Market; Ind-Swift Introduces Sibuslim-10; Wellnx Launches NV; Iron-Tek Introduces Appetite Suppressant; Yamanouchi and Keio University Discover Target; 8.Recent Industry Activity; Pfizer Halts CP-945, 598 Development; Shionogi to Acquire Sciele Pharma; Anthill Inks Agreement with Zafgen; EMEA Suspends Acomplia; GlaxoSmithKline to Sell Alli as OTC Drug; Sanofi-Aventis to Market Acomplia in UK; Orexigen Receives 4th US Patent for Contrave; BELLUS Health to Acquire Innodia; Ore Secures License to Develop Romazarit; GlaxoSmithKline Receives FDA Approval for Orlistat; Pfizer Receives Approval for Slentrol; GlaxoSmithKline Secures Licensing Rights of Orlistat; Pfizer Collaborates with Bristol-Myers Squibb; Takeda Collaborates with LG Life Sciences; Takeda to Acquire Paradigm; Sanofi-Aventis Secures Reimbursement Status; AstraZeneca Inks Agreement with Palatin Technologies; Switzerland Includes Acomplia in Reimbursement List; Allergan Pockets EndoArt; Sanofi-Aventis Receives Approval for Acomplia; Biocon Inks MoU with Neopharma; Aurigene Partners with Forest Laboratories; Pfizer Licenses Obesity Compounds from Bayer; Merck Terminates Collaboration with Nastech; Sanofi-Aventis to Receive Rights for Rimonabant; UMN Pharma Inks Agreement with Crucell and; 7TM Pharma Pockets CareX SA; BioLineRx Inks Licensing Agreement with Yissum; Aegis Inks Licensing Agreement with Albany; Manhattan’s Obesity Drug Approved for Human Trials; Chugai Halts Development of Anti-Obesity Agent; HSG Acquires Polymann; Orchid Pockets Bexel; 9.Focus on Select Players; Abbott Laboratories (US); Alizyme Plc (UK); Amylin Pharmaceuticals, Inc. (US); AstraZeneca Plc (UK); F. HOFFMANN-LA ROCHE LTD. (Switzerland); GlaxoSmithKline Plc (UK); Sanofi-Aventis SA (France); SuperGen, Inc. (USA); Takeda Pharmaceutical Company Limited (Japan); VIVUS, Inc. (US); 10.Global Market Perspective; Table 6: World Recent Past, Current & Future Market Analysis for Anti-Obesity Drugs by Geographic Region - US, Europe; Table 7: World 10-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Dollar Sales
III. MARKET: 1.The United States; A. Market Analysis; Market Overview; Obesity Rate; Statistical Data; Reimbursement Scenario; Regulatory Environment; Obesity and Related Ailments: Burden on Societal and; Competition; Recent Clinical Trials; Product Approval/Launches; Strategic Corporate Developments; Review of Major Players; B. Market Analytics; Table 15: US Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed; 2.Europe; A. Market Analysis; Market Overview; Lack of Reimbursement: Barrier to Market; Statistical Data; Overview of Novel Policies Adopted by Select European; B. Market Analytics; Table 18: European Recent Past, Current & Future; Table 19: European 10-Year Perspective for Anti-Obesity Drugs by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy,; 2a.France; A. Market Analysis; Market Overview; Product Approval/Launches; Strategic Corporate Developments; Sanofi-Aventis SA - A Key Player; B. Market Analytics; Table 20: French Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005; 2b.Germany; A. Market Analysis; Table 21: German Anti-obesity Drugs Market (2005 and 2006): Percentage Share Breakdown of Volume Sales by Leading Brands - Meridia and Xenical and Others; B. Market Analytics; Table 22: German Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005; 2c.Italy; Table 23: Italian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005; 2d.The United Kingdom; A. Market Analysis; Market Overview; Recent Clinical Trials; Product Approval/Launches; Strategic Corporate Developments; Review of Major Players; B. Market Analytics; Table 25: UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005; 2e.Rest of Europe; A. Market Analysis; Recent Clinical Trials; Product Approval/Launches; Strategic Corporate Developments; F. HOFFMANN-LA ROCHE LTD. - A Key Player; B. Market Analytics; Table 26: Rest of Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes; 3.Rest of World; A. Market Analysis; Brief Review of Select Regions; Table 27: Canadian Obesity Prevalence; Table 28: Canadian Adult Overweight and Obesity Prevalence (2004): Breakdown of Population; Australia; China; India; Companies; Japan; A Key Player; Korea; New Zealand; Recent Clinical Trials; Product Approval/Launches; Strategic Corporate Developments; B. Market Analytics; Table 30: Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes
IV. COMPETITIVE LANDSCAPE

Abstract

This report analyzes the worldwide markets for Anti-Obesity Drugs in Millions of US$. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2005 through 2015. The report profiles 85 companies including many key and niche players worldwide such as Abbott Laboratories, Alizyme Plc, Amylin Pharmaceuticals, Inc., AstraZeneca Plc., F.HOFFMANN-LA ROCHE LTD., GlaxoSmithKline Plc, Sanofi-Aventis SA, SuperGen, Inc., Takeda Pharmaceutical Company Limited, and VIVUS, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Titles available via "online download" are not affected by this and are still delivered to your reading room immediately.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Anti-Obesity Drugs

Table of Contents

Abstract